Log In
BCIQ
Print this Print this
 

AG013

  Manage Alerts
Collapse Summary General Information
Company Intrexon Corp.
DescriptionActoBiotic genetically modified to express and secrete human trefoil factor 3 (TFF3)
Molecular Target Trefoil factor 3 (TFF3)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationMucositis
Indication DetailsTreat and prevent oral mucositis (OM); Treat and prevent oral mucositis (OM) in head and neck cancer patients
Regulatory Designation U.S. - Fast Track (Treat and prevent oral mucositis (OM));
EU - Orphan Drug (Treat and prevent oral mucositis (OM))
PartnerOragenics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$60.0M

$30.0M

0


 Deals Details
Get a free BioCentury trial today